We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
New insights into the burden and costs of multiple sclerosis in Europe: Results for the Netherlands.
- Authors
Uitdehaag, Bernard; Kobelt, Gisela; Berg, Jenny; Capsa, Daniela; Dalén, Johan
- Abstract
Introduction: To estimate the value of interventions in multiple sclerosis (MS) – where lifetime costs and outcomes cannot be observed – outcome data have to be combined with costs. This requires that cost data be regularly updated. Objectives and Methods: This study is part of a cross-sectional retrospective study in 16 countries collecting data on resource consumption and work capacity, health-related quality of life (HRQoL) and prevalent symptoms for patients with MS. Descriptive analyses are presented by level of severity, from the societal perspective, in EUR 2015. Results: A total of 382 patients (mean age: 54 years) participated in the Netherlands; 81% were below retirement age and of these, 31% were employed. Employment was inversely related to disease severity, and MS affected productivity at work for 82% of patients. Overall, 96% and 73% of patients experienced fatigue and cognitive difficulties, respectively, as a problem. Mean utility and annual costs were 0.744 and €23,100 at Expanded Disability Status Scale (EDSS) 0–3, 0.595 and €32,300 at EDSS 4–6.5, and 0.297 and €50,500 at EDSS 7–9. The mean cost of a relapse was estimated at €3000. Conclusion: This study provides current data on MS in the Netherlands that are important for the development of health policies and to estimate the value of current and future treatments.
- Subjects
NETHERLANDS; MULTIPLE sclerosis research; WORK capacity evaluation; QUALITY of life; MULTIPLE sclerosis; FATIGUE (Physiology); COGNITION disorders; HEALTH policy; PATIENTS
- Publication
Multiple Sclerosis Journal, 2017, Vol 23, p117
- ISSN
1352-4585
- Publication type
Article
- DOI
10.1177/1352458517708663